SCHEMBL665674

SCHEMBL665674

CCN(C)C(=O)CN1CCNCC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.61
CHRM5 P08912 2/20 0.46
CHRM3 P20309 2/20 0.46
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MDM2 Q00987 1/20 0.33
BCHE P06276 1/20 0.33
BIRC2 Q13490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11608912 0.83 SIGMAR1 (0.66) SIGMAR1CHRM5CHRM3ALDH1A1KMT2A
SCHEMBL5863 0.82 SIGMAR1 (0.56) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
Hydrochloric Acid SCHEMBL963162 0.81 ALDH1A1 (0.54) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
SCHEMBL792209 0.81 SIGMAR1 (0.49) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
Hydrochloric Acid SCHEMBL17271878 0.81 ALDH1A1 (0.54) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
Piperazine SCHEMBL28845954 0.81 SIGMAR1 (0.54) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
SCHEMBL7748189 0.81 SIGMAR1 (0.54) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
SCHEMBL24029891 0.80 SIGMAR1 (0.52) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
SCHEMBL3997780 0.80 SIGMAR1 (0.52) SIGMAR1CHRM5CHRM3ALDH1A1MEN1
SCHEMBL14724826 0.79 HTR1A (0.44) SIGMAR1ALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788351-A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2014-10-15 EP claimed
WO-2013050446-A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-04-11 WO claimed
US-10703754-B2 Compounds and compositions for treating chemical warfare agent-induced injuries ELI LILLY AND COMPANY (US) 2020-07-07 US disclosed
US-20190194202-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELI LILLY AND COMPANY 2019-06-27 US disclosed
US-20180265511-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELI LILLY AND COMPANY 2018-09-20 US disclosed
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2018-05-17 US disclosed
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS HYDRA BIOSCIENCES, INC. 2013-03-07 US disclosed
US-20120046305-A1 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS ELI LILLY AND COMPANY 2012-02-23 US disclosed
US-20090143377-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10703754-B2 Compounds and compositions for treating chemical warfare agent-induced injuries ELANE, CASP3, MMP8 SIGMAR1 4506/4885CHRM5 3712/4885CHRM3 1467/4885
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 SIGMAR1 523/4885CHRM5 932/4885CHRM3 344/4885
US-20180265511-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 SIGMAR1 4506/4885CHRM5 3712/4885CHRM3 1467/4885
US-20090143377-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 SIGMAR1 523/4885CHRM5 932/4885CHRM3 344/4885
US-20120046305-A1 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS TRPA1, TRPV1, TRPV3 SIGMAR1 896/4885CHRM5 293/4885CHRM3 33/4885
US-20190194202-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 SIGMAR1 4506/4885CHRM5 3712/4885CHRM3 1467/4885
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 SIGMAR1 523/4885CHRM5 932/4885CHRM3 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.